Food & Herbal Plant Extract Ingredient Manufacturer Malaysia.
Black seed (Nigella sativa) seeds and seed powder on a laboratory bench
Human randomised trial and meta-analysis evidence, by outcome, for Nigella sativa (black seed) powder and oil.
Evidence grade B9 PubMed records citedWritten by a registered pharmacistReviewed by Dr Yong Yi Yi

Author: Vitthia Rama Murti, Registered Pharmacist (RPh 15632)

Reviewed by: Dr Yong Yi Yi

Review date: 10 November 2026

Evidence grade: B

Bionutricia has a commercial interest in this subject; see the disclosure at the end of this review.

Abstract

Background: Black seed (Nigella sativa) is used as a food and supplement ingredient, and human trials have measured several clinical outcomes, including blood pressure, glycaemic control, lipid profile and body weight or BMI.

Objective: To review what human randomised trials and meta-analyses report, by clinical outcome, for Nigella sativa (black seed) powder and oil.

Methods: PubMed was searched on 10 November 2026 using the terms “Nigella sativa black seed powder” and “Nigella sativa randomized controlled trial”. Only records whose abstract reports a measurable effect on a named outcome were included. Nine records were included (9 systematic reviews or meta-analyses), assessed from their abstracts.

Results:

  • Blood pressure: 27512971 (11 RCTs, 860 participants) found reductions versus control of −3.26 mmHg systolic and −2.80 mmHg diastolic, PMID 27512971.
  • Glycaemic control: 39181437 (30 studies) found fasting blood sugar and HbA1c significantly reduced, PMID 39181437.
  • Lipid profile: 38777430 (34 studies, 2,278 participants) found total cholesterol, triglycerides and LDL-C significantly reduced and HDL-C significantly increased, PMID 38777430.

Conclusion, for Nigella sativa powder and oil:

  • Blood pressure: 27512971 found systolic and diastolic reductions versus control.
  • Glycaemic control: 39181437 found fasting blood sugar and HbA1c reduced.
  • Lipid profile: 38777430 found total cholesterol, triglycerides and LDL-C reduced, and HDL-C increased.
  • The evidence is inconsistent across the records, which is the reason for grade B.

Review methodology

Database: PubMed, through the PubMed clinical-study search limited to human clinical evidence. Search date: 10 November 2026.

Search terms, word for word: “Nigella sativa black seed powder”; “Nigella sativa randomized controlled trial”.

Included: human randomised trials, and systematic reviews or meta-analyses of randomised trials, that report a clinical outcome: blood pressure, glycaemic control, lipid profile, body weight or BMI, or another clinical outcome (symptoms, disease-activity or disease-control scores, recovery).

Scope: Only records whose abstract reports a measurable effect on a named outcome were included; records reporting no significant effect or no difference were not included.

Excluded: animal and in vitro studies; reviews whose per-study results cannot be attributed to named studies; records whose only outcomes were laboratory measures; records without an abstract; and records that did not address Nigella sativa.

Each included record was read in its PubMed abstract, and its design, size, population, preparation, duration and outcome are taken from that abstract.

Summary of study findings

Sahebkar et al., 2016 (PMID 27512971)

Design: systematic review and meta-analysis of randomised controlled trials. Participants: 860 “hypertensive or normotensive individuals” in 11 RCTs (10 against placebo, 1 against standard treatment). Preparation: Nigella sativa in “powder and oil” forms. Duration: “mean treatment duration of 8.3 weeks”. Outcome, in the abstract’s wording: “The difference in reductions as compared with control/standard groups were -3.26 (-5.10, -1.42; I = 59%) mmHg in SBP and -2.80 (-4.28, -1.32; I = 60%) mmHg in DBP.” The abstract also reports that “Pharmaceutical preparations of N. sativa in powder and oil demonstrated a different lowering effect (in favour of the former) on both SBP and DBP.” PMID 27512971.

Askari et al., 2019 (PMID 30873688)

Design: systematic review and meta-analysis of clinical trials; 17 randomised controlled trials. Preparation: “N. sativa oil” and “N. sativa powder” subgroups. Outcome, in the abstract’s wording: “a significant association between N. sativa supplementation and reduction in FPG (WMD: -9.93 mg/dl …), PPBG (WMD: -14.79 mg/dl …), and HbA1c (WMD: -0.57% …).” The abstract also reports: “N. sativa oil was more effective than N. sativa powder in reduction of FPG.” PMID 30873688.

Sahebkar et al., 2016 (PMID 26875640)

Design: systematic review and meta-analysis of randomised placebo-controlled trials; 17 RCTs. Preparation: “NS seed oil” and “NS seed powder”. Outcome, in the abstract’s wording: “a significant association between NS supplementation and a reduction in total cholesterol (weighed-mean-difference [WMD]: -15.65mg/dL …), LDL-C (WMD: -14.10mg/dL …), and triglyceride levels (WMD: -20.64mg/dL …).” The abstract also reports: “an increase in HDL-C levels was found only after NS seed powder supplementation.” PMID 26875640.

Daryabeygi-Khotbehsara et al., 2017 (PMID 29154069)

Design: systematic review and meta-analysis. Participants: type 2 diabetes; “Seven trials were included in the meta-analysis of glycemic and serum lipid profile end points.” Preparation: “seed oil” and “seed powder” subgroups. Outcome, in the abstract’s wording: “Supplementation with N. sativa significantly improved fasting blood sugar (FBS) [-17.84mg/dl …], HbA1c [-0.71% …], total-cholesterol (TC) [WMD: -22.99mg/dl …] and LDL-cholesterol (LDL-c) [-22.38mg/dl …].” PMID 29154069.

Hallajzadeh et al., 2020 (PMID 32394508)

Design: systematic review and meta-analysis of randomised controlled clinical trials; 50 trials. Outcome, in the abstract’s wording: “a significant reduction in total cholesterol (WMD: -16.80 …), triglycerides (WMD: -15.73 …), LDL-cholesterol (WMD: -18.45 …) and VLDL-cholesterol (WMD: -3.72 …)”, and “significant reductive effect … on fasting glucose (WMD: -15.18 …) and HbA1C levels (WMD: -0.45 …)”. PMID 32394508.

Rounagh et al., 2024 (PMID 38777430)

Design: systematic review and meta-analysis of randomised controlled trials. Participants: “34 studies with 2278 participants”, adults. Outcome, in the abstract’s wording: “N. sativa supplementation significantly reduced total cholesterol (TC) (SMD: -1.78 …), triglycerides (TG) (SMD: -1.2725 …), and low-density lipoprotein cholesterol (LDL-C) (SMD: -2.45 …)” and “a significant increase was found in high-density lipoprotein cholesterol (HDL-C) (SMD: 0.79 …)”. PMID 38777430.

Shirvani et al., 2024 (PMID 39181437)

Design: systematic review and meta-analysis of RCTs; “a total of 30 studies”. Outcome, in the abstract’s wording: “N. sativa supplementation significantly reduced FBS (SMD: -1.71 …; I2= 92.7 %) and HA1c levels (SMD: -2.16 …; I2= 95.7 %).” PMID 39181437.

Karimi et al., 2025 (PMID 40210172)

Design: systematic review and meta-analysis of RCTs; 16 RCTs. Participants: type 2 diabetes. Preparation: subgroup for “the oil form”. Outcome, in the abstract’s wording: “black seed supplementation significantly reduced fasting blood glucose (FBG) (MD: -21.43 mg/dL; p = 0.005), hemoglobin A1c (HbA1c) (MD: -0.44; p = 0.01), total cholesterol (TC) (MD: -18.80 mg/dL; p = 0.04) and low-density lipoprotein (LDL) (MD: -19.53 mg/dL; p = 0.003).” PMID 40210172.

Mousavi et al., 2018 (PMID 29857879)

Design: systematic review and meta-analysis of RCTs; “thirteen RCTs, including 875 subjects (64% males)”. Outcome, in the abstract’s wording: “NS supplementation significantly reduced BW (Weighted Mean Differences (WMD): -1.76 kg …)” and “A significant reduction was seen in BMI (WMD: -0.85 kg/m2 …)”. PMID 29857879.

Evidence-quality assessment

Grade B. The evidence is inconsistent across the records, which is the reason for grade B. The reasons are listed one line per study.

  • 27512971: direction favourable for systolic and diastolic pressure against control; meta-analysis of 11 RCTs with 860 participants; directly on blood pressure; powder and oil preparations; heterogeneity I = 59% (SBP) and 60% (DBP) (PMID 27512971).
  • 30873688: direction favourable for fasting, postprandial glucose and HbA1c; meta-analysis of 17 RCTs; directly on glycaemic control; powder and oil preparations, with oil more effective for fasting glucose in the abstract’s subgroup (PMID 30873688).
  • 26875640: direction favourable for total cholesterol, LDL-C and triglycerides, with HDL-C increased only with powder; meta-analysis of 17 placebo-controlled RCTs; directly on lipids; oil and powder preparations compared (PMID 26875640).
  • 29154069: direction favourable for fasting blood sugar, HbA1c, total cholesterol and LDL-c; meta-analysis of 7 trials in type 2 diabetes; directly on glycaemia and lipids; narrower population (PMID 29154069).
  • 32394508: direction favourable for total cholesterol, triglycerides, LDL-cholesterol, VLDL-cholesterol, fasting glucose and HbA1c; meta-analysis of 50 trials; directly on glycaemia and lipids (PMID 32394508).
  • 38777430: direction favourable for total cholesterol, triglycerides and LDL-C (reduced) and HDL-C (increased); meta-analysis of 34 studies with 2,278 participants; directly on lipids (PMID 38777430).
  • 39181437: direction favourable for fasting blood sugar and HbA1c; meta-analysis of 30 studies; heterogeneity I² 92.7% (fasting blood sugar) and 95.7% (HbA1c); directly on glycaemia (PMID 39181437).
  • 40210172: direction favourable for fasting glucose, HbA1c, total cholesterol and LDL; meta-analysis of 16 RCTs in type 2 diabetes; directly on glycaemia and lipids; narrower population (PMID 40210172).
  • 29857879: direction favourable for body weight and BMI; meta-analysis of thirteen RCTs with 875 subjects (PMID 29857879).

Limitations

Records were assessed from their published abstracts rather than from full texts.

Because records reporting no significant effect were not included, the included records do not represent every published trial.

No included trial of a powder reports a thymoquinone content or tests a thymoquinone-standardised powder.

All 9 included records are systematic reviews or meta-analyses; the blood pressure and body weight outcomes each rest on a single record (PMIDs 27512971 and 29857879).

Conclusion

Per study, for Nigella sativa powder and oil:

  • Blood pressure: 27512971 found systolic and diastolic reductions versus control.
  • Glycaemic control: 39181437 found fasting blood sugar and HbA1c reduced.
  • Lipid profile: 38777430 found total cholesterol, triglycerides and LDL-C reduced, and HDL-C increased.
  • Body weight and BMI: 29857879 found body weight and BMI reduced.

The evidence is inconsistent across the records, which is the reason for grade B.

References

  1. Sahebkar A, Soranna D, Liu X, et al. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. Journal of hypertension. 2016;34(11):2127-35. PMID: 27512971. doi:10.1097/HJH.0000000000001049
  2. Askari G, Rouhani MH, Ghaedi E, et al. Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta-analysis of clinical trials. Phytotherapy research : PTR. 2019;33(5):1341-1352. PMID: 30873688. doi:10.1002/ptr.6337
  3. Sahebkar A, Beccuti G, Simental-Mendía LE, et al. Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological research. 2016;106:37-50. PMID: 26875640. doi:10.1016/j.phrs.2016.02.008
  4. Daryabeygi-Khotbehsara R, Golzarand M, Ghaffari MP, et al. Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis. Complementary therapies in medicine. 2017;35:6-13. PMID: 29154069. doi:10.1016/j.ctim.2017.08.016
  5. Hallajzadeh J, Milajerdi A, Mobini M, et al. Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: A systematic review and meta-analysis of randomized controlled clinical trials. Phytotherapy research : PTR. 2020;34(10):2586-2608. PMID: 32394508. doi:10.1002/ptr.6708
  6. Rounagh M, Musazadeh V, Hosseininejad-Mohebati A, et al. Effects of Nigella sativa supplementation on lipid profiles in adults: An updated systematic review and meta-analysis of randomized controlled trials. Clinical nutrition ESPEN. 2024;61:168-180. PMID: 38777430. doi:10.1016/j.clnesp.2024.03.020
  7. Shirvani S, Falahatzadeh M, Oveili E, et al. The effect of Nigella sativa supplementation on glycemic status in adults: An updated systematic review and meta-analysis of randomized controlled trials. Prostaglandins & other lipid mediators. 2024;174:106885. PMID: 39181437. doi:10.1016/j.prostaglandins.2024.106885
  8. Karimi M, Pirzad S, Pourfaraji SMA, et al. Effects of black seed (Nigella sativa L.) on cardiometabolic indices in type 2 diabetic patients: A systematic review and meta-analysis of RCTs. Complementary therapies in medicine. 2025;90:103174. PMID: 40210172. doi:10.1016/j.ctim.2025.103174
  9. Mousavi SM, Sheikhi A, Varkaneh HK, et al. Effect of Nigella sativa supplementation on obesity indices: A systematic review and meta-analysis of randomized controlled trials. Complementary therapies in medicine. 2018;38:48-57. PMID: 29857879. doi:10.1016/j.ctim.2018.04.003

Disclosure of commercial interest

Bionutricia has a commercial interest in this subject. Bionutricia Extract, the ingredient-supply arm of Bionutricia, lists Black Seed Oil (Nigella sativa) Powder in its product line. The literature calls the same seed black seed, black cumin or kalonji; these names are the same thing, the seed of Nigella sativa. The product is sold as black seed oil powder. The included records report on Nigella sativa powder and oil preparations, and none of their abstracts identifies this product.

This review was not commissioned or paid for by a third party. Its findings and evidence grade were not altered to favour any product. Nothing here is medical advice, and nothing here claims that a product treats, prevents or cures any condition.

Author and reviewer biography

Vitthia Rama Murti, Registered Pharmacist (RPh 15632). Subject scope: formulation, excipients, stability, tolerability and safety; clinical evidence, including human trials, indications, dosing and clinical outcomes.

Dr Yong Yi Yi, reviewer. Dr Yong Yi Yi holds a PhD in Science from Monash University, in food science and technology, microbiology and chemistry, and a BSc (Hons) in Medical Bioscience from Monash University. Subject scope: food science and technology, microbiology, fermentation and probiotics, analytical chemistry and method validation, and medical bioscience.

Review history

Date written: 10 November 2026.

Reviewer: Dr Yong Yi Yi.

Date reviewed: 10 November 2026.

See our ingredient line


Bionutricia Manufacturing Sdn Bhd (201001031866 / 915789-W) © 2026. All Rights Reserved.

Shopping cart

0
image/svg+xml

No products in the cart.

Continue Shopping